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Abstract
Background: Viral and bacterial infections have been considered as a risk factor for Coronary
Heart Disease (CHD). NK cells, as a first line of defense against those infections, may play a role
in CHD development. Thus, the main aim of our study was to determine NK cell compartment in
patients with CHD undergoing coronary artery by-pass grafting.
Results:  Ninety three patients with CHD were included into the study; the control group
consisted of 49 healthy volunteers. As compared to controls, CHD patients had lower NK
cytotoxic activity. CHD group had also a decreased absolute number and percentage of total NK
cells and CD3-CD56dim cytotoxic NK subset. In addition, we observed tendency toward lower
percentage of the CD3-CD56bright regulatory NK subset and CD3-CD56+IFN-γ+ cells in CHD
patients.
Conclusion:  These data indicate that CHD is associated with an impairment of NK cells
compartment.
Background
NK are a component of nonspecific immune response
involved in the defense against viral and bacterial infec-
tions [1]. It is well-proved that these cells play an impor-
tant regulatory role in the innate immune response. Based
on the CD56 cell surface receptor density, human NK cells
may be divided into two distinct subpopulations, i.e.
CD56dim and CD56bright NK cells [2]. The CD56dim
cells comprise about 90% of CD56 positive NK cells [3].
They exert the cytotoxic effect through perforins and
granzymes [1]. These cells also possess the ability to form
conjugates with appropriate target cells [4]. In contrast,
the CD56bright cells are involved in the regulation of
innate immune response through secretion of an array of
cytokines, such as IFN-γ, TNF-β, IL-10, IL-13 and GM-CSF
[5,6]. When quiescent, the CD56bright NK cells are less
cytotoxic than CD56dim NK cells.
Coronary heart disease (CHD) has been regarded as a dis-
ease which aetiology might be at least in part related to
chronic infections and prolonged inflammatory state
[7,8]. Apart from classical risk factors such as metabolic
disorders, hypertension, diabetes and age, also infections
and pathogen burden have been considered as a potential
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risk factor for CHD. The main suspects linked to the vas-
cular disease are wide-spread organisms such as cytomeg-
alovirus (CMV) and Chlamydia pneumoniae. DNA of these
pathogens was found in early atherosclerotic lesions
[9,10]. Also animal models confirmed an association
between infections and vascular diseases. It was found
that infections with CMV, as well as with Chlamydia pneu-
moniae, accelerate development of atherosclerosis in
ApoE-/- mice [11,12].
Clearly, as infections deteriorate the course of CHD and
NK cells are the first line of defense against infections,
there might be a link between development of CHD and
NK cells. In 1997 Ogata and coworkers showed that low
NK cytotoxic activity in the elderly correlates with a his-
tory of severe infections or death due to infections [13].
Moreover, the decrease in NK cell cytotoxic activity is
related to susceptibility to common infectious diseases in
the elderly [14]. It was also postulated that the number of
NK cells correlates positively with age, which is regarded
as a possible compensation for decrement of NK cell cyto-
toxicity during ageing [15]. Decreased NK cells cytotoxic
response with age was observed by Mariani and colleagues
[16]. However, when very healthy elderly people were
selected the decrease in cytotoxic activity was not found
[17]. Thus, it may be concluded that so called "healthy
ageing" is connected with higher number of NK cells and
preserved NK cell cytotoxic response.
It is also worth to mention that in the elderly, NK cells
constitute the main mechanism of antiviral defense [18].
Moreover, cytotoxic activity of these cells may be modu-
lated during infections by both bacteria and viruses [19-
21]. Also inflammation affects NK cell functions; our pre-
vious studies showed that high concentration of proin-
flammatory cytokines correlates with low NK cytotoxic
activity [22,23]. Similar data were obtained in sepsis [24].
NK activity is a key component of immune defence
against obligate, intracellular bacterial and viral patho-
gens. Their low activity may lead to the development of
persistent infections and its late consequences including
enhanced risk of CHD. Not to mention that inflammation
connected with CHD may further decrease NK cell func-
tions. Thus, we aimed to characterise NK cell compart-
ment, i.e. CD56dim/bright NK cell number and their
cytotoxic activity in patients with long-lasting CHD. We
found that the CHD patients had lower NK cytotoxic
activity, decreased absolute number and percentage of
total NK cells as well as the CD3-CD56dim cytotoxic NK
subset and, CD3-CD56bright regulatory NK subset.
Results
Basic clinical data
As it is shown in Table 1, there were no differences in age
and sex between the CHD and control groups. Not sur-
prisingly, the percentage of people with a smoking history
as well as individuals suffering from hypertension was
higher in the group with coronary heart disease. Addition-
ally, the groups differed in a spectrum of medical treat-
ment. None of the drugs influenced significantly the
examined parameters of NK activity.
NK cells activity
Our first approach aimed at specifying the activity of nat-
ural killer cells in the groups. We estimated it by both, NK
cells cytotoxic assay and by measuring of IFN-γ intracellu-
lar production in CD3-CD56+ cells. There were significant
differences in the NK cytotoxic activity and intracellular
production of IFN-γ between the patients and the control
group (Table 2). Natural killer cells from CHD group were
less cytotoxic than those from healthy individuals. We
also observed tendency towards lower production of
intracellular IFN-γ by NK cells in CHD group (p = 0,07).
Circulating NK cell subsets
Next we asked a question, if the lower NK activity in the
patients with coronary heart disease may be connected
with changes in the composition of NK compartment. To
address this issue we studied changes in the number of
total NK cells, the CD3-CD56bright NK regulatory cells
and the CD3-CD56dim NK cytotoxic cells by flow cytom-
etry. The percentage of circulating NK cells (CD3-CD56+),
measured within lymphocyte gate, was lower in CHD
patients than in the control group (p = 0,00003). Simi-
larly, the CD3-CD56dim cells were less frequent in CHD
group (p = 0,00005, Fig. 1). We found also a trend
towards the difference in the percentage of CD3-
CD56bright cells (p = 0,06, Fig. 1). These results were con-
firmed by the analysis of total number of circulating NK
cells (Table 3). The absolute values of CD3-CD56+ and
CD3-CD56dim cells were lower in CHD group as com-
pared to the control group. Furthermore, the absolute
number of leucocytes was higher in CHD group than in
the control group.
Smoking, medical treatment and NK cells
There was no significant effect of smoking and medical
treatment on NK cells subsets and functions (p > 0,1).
Discussion
Results of our paper revealed that patients with coronary
heart disease are characterized by lower cytotoxic NK
activity as compared to age-matched healthy control
group. CHD patients had significantly lower absolute
number and percentage of total NK cells as well as the
main cytotoxic NK subset, i.e. CD56dim cells. The per-Immunity & Ageing 2007, 4:3 http://www.immunityageing.com/content/4/1/3
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centage of regulatory NK subset CD56bright was also
lower in CHD patients, however, the difference did not
reach statistical significance. Production of intracellular
IFN-γ in CD3-CD56+ NK cells, which may be considered
as a marker of NK activity, was slightly lower in CHD
patients.
Our results complement and extended previous studies of
Bruunsgaard [25] and Jonasson [26] who have docu-
mented NK cells impairment in cardiovascular diseases.
Bruunsgaard revealed that patients with low ankle-
branchial arterial pressure index, which indicates an early,
symptom-free stage of atherosclerosis, are characterized
by low cytotoxicity per NK cell. However, total NK cell
cytotoxic activity in Bruunsgaard's study was similar to the
control group as CHD patients had slightly higher
number of NK cells. It is worthy to stress out that the Bru-
unsgaard's data illustrates the changes in NK cells com-
partment in an early atherosclerosis and not in fully
symptomatic CHD, which can explain discrepancy
between this report and our study.
Study of Jonasson [26] showed that patients with stable
angina are characterized by a decrease in NK cell cytotoxic
activity. Our work confirmed this finding and provided
some novel data. In Jonasson's studies only the percent-
age of total CD3-CD56+ NK cells and its CD3-CD56dim
subset were decreased in CHD patients. In contrast to our
study, they did not find a difference in the absolute
number of those cells. We found a trend towards lower
percentage of the CD3-CD56bright cells in CHD patients
in comparison to healthy controls. Furthermore, we also
revealed that NK cells from CHD patients produced less
IFN-γ which may explain their lower cytotoxic activity.
However it has to be reminded that this data was at the
edge of significance.
Table 2: NK cells activity
CHD Group n = 93 Control group n = 49 p
The percentage of NK cells cytotoxic activity 26,83, 18,61/40,03 36,85, 24,94/43,23 0,04
The percentage of CD3-CD56+IFN-γ cells 4,58, 2,72/7,8 6,38, 4,03/9,83 0,07
The results are shown as median, 25th percentile/75th percentile.
All the differences were calculated by the U-Mann Whitney test.
Table 1: Basic clinical data
CHD patients (n = 93) Control group (n = 49) p
Age (years)(median, 25th percentile/75th percentile) 63, 57/69 64, 58/73 0,43
Men (%) 56,99 42,86 0,11
Hypertension (%) 79,78 10,20 0,0000
Diabetes (%) 37,08 0 -












NYHA, median, interquartile range 0, 0–1 - -
CCS, median, interquartile range 2, 2–3 - -
EuroSCORE, median, interquartile range 3, 1–4 - -
Medicines (%)
β-blockers 80,85 6 0,0000
Statins 82,98 0 -
Ca – blockers 18,08 4 0,45
Nitrates 55,32 2 0,0000
Diuretics 23,40 2 0,07
Spironolacton 6,38 0 -
Insulin 14,89 0 -
Oral anti-diabetics 22,34 0 -
ASA 91,49 0 -
Digoxin 0 0 -
ACE inhibitors 72,34 0 -
The results are shown as median, 25th percentile/75th percentile.Immunity & Ageing 2007, 4:3 http://www.immunityageing.com/content/4/1/3
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The reason why our study is novel comes from the fact
that our experimental group is different from those previ-
ously analyzed. Bruunsgaard [25] analyzed patients with
an early atherosclerosis. Jonasson studied more pro-
gressed patients but they were younger than our cohort
and still they did not reach the stage requiring CABG sur-
gery. It seems that changes in NK cell compartment are
progressing with CHD development. That's why in the
previous studies, which examined group of patients with
early stages of CHD, impairment of NK cells compartment
Table 3: Absolute values of circulating leukocytes, lymphocytes and NK cells
Number of cells per μL CHD Group n = 93 Control group n = 49 p
leukocytes 7300, 6120/8820 6180, 5170/7450 0,006
lymphocytes 1990,4, 1642,98/2463,73 1939,36, 1505,92/2633,4 0,87
CD3-CD56+ cells 200,8, 135,99/265,33 322,75, 188,26/470,68 0,007
CD3-CD56dim cells 191,163, 130,13/261,07 317,54, 186,17/451,15 0,008
CD3-CD56bright cells 6,5, 3,77/10,94 8,32, 2,46/21,08 0,35
The results are shown as median, 25th percentile/75th percentile.
All the differences were calculated by the U-Mann Whitney test.
Percentage of circulating NK cell subsets Figure 1
Percentage of circulating NK cell subsets. The results were analyzed by the U Mann Whitney test. Patients with CHD n 
= 93; control group n = 49. * p = 0,00003, ** p = 0,00005, # p = 0,06. The results are presented as median, 25th percentile/
75th percentile.Immunity & Ageing 2007, 4:3 http://www.immunityageing.com/content/4/1/3
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was not so extensive. Thus, the measuring of NK cells sta-
tus may be considered as an indicator of health risk in
patients with cardiovascular disorders.
In the light of the current literature the loss of NK cell
functions may have an important impact on patients with
CHD. The cytotoxic activity of natural killer cells may be
considered as a predictor of long life and a marker of
immune status. Centerians have higher NK values in rela-
tion to middle aged people and similar to the young ones
[18]. Along with the cytotoxic function also the CD3-
CD56dim cells, the subset with high cytotoxic properties,
was found to be enlarged in the elderly [27]. Successful
aging was connected with a high NK cytotoxic activity and
increased number of the total NK compartment. Results of
our study indicate that in patients with advanced CHD the
remodeling of NK cells compartment is disadvantageous.
This indicates that CHD patients are affected both by the
coronary vessel disease and deficiency of NK cell activity.
Searching for culprits of immunosuppression in CHD
patients, the role of pathogens has to be considered.
Recently, infections have been regarded as a potential risk
factor for coronary heart disease. The main suspects linked
to the vascular disease are herpesvirus, cytomegalovirus
(CMV) and gram negative bacteria. These pathogens may
depress immune system in different ways. In the early
phase of infection cytomegalovirus causes release of IL-10
[28]. Similarly, production of IL-10 by monocytes is ele-
vated during the infection with Chlamydia pneumoniae
[29]. IL-10 is a cytokine which directly influences NK cells
quenching their cytotoxic activity [30]. IL-10 counteracts
IL-2 secretion, which results in decrease of NK cell func-
tion [31,32]. Moreover, an increase of the CD8+CD28-
CD57+ T cells was observed during CMV long-term per-
sistent infection [33]. The expansion of these cells was
also reported in CHD patients, and the number of these
cells correlated positively with anti-CMV IgG titers [34].
The CD8+CD28-CD57+ T cells are considered to be
mostly CMV specific and expansion of these cells is not
neutral for NK cells. In 1991 Autran and coworkers
showed that the CD8+ CD57+ may have suppressive
effect on NK cells functions [35]. These data indicate that
an active infection with specific pathogens may affect NK
cells functions. Vice versa, low NK activity may be one of
the possible gates of spreading infection, and this may be
a way of deepening of NK cell deficiency. Altogether, it
creates a positive feedback loop leading to accelerated
progress of diseases associated with chronic infections.
This mechanism has a primary meaning in ageing. Ogata
and colleagues studies suggested that low NK cells activity
is a marker of past infections and also a predicting factor
of short survival due to infections in elderly people
[13,14]. Thus, low cytotoxic activity of NK cells is a factor,
which connects health status of CHD patients with their
susceptibility to infections.
The tendency towards decrease of the level of CD3-
CD56bright cells found in our study fits with the hypo-
thesis that NK cell functions deteriorate due to chronic
inflammation. It has been suggested that CD3-
CD56bright cells are very capable of migrating to the sites
of local inflammation where they enhance inflammation
by the stimulation of TNF-α production by monocytes
[36]. Thus, decreased number of CD3-CD56bright cells in
the peripheral blood of CHD patients may suggest their
trafficking to the tissues affected by inflammatory process,
such as artery walls, in which they accelerate unprofitable
changes such as atherosclerosis.
It is also worth to mention that decrease in NK cells cyto-
toxic activity may be a consequence of proinflammatory
effect exerted by cytokines. Our previous paper showed
that older people suffering from different disorders are
characterized by elevated level of these cytokines and
simultaneously by low NK activity [37]. Coronary heart
disease is associated with an increase of proinflammatory
cytokines concentrationy [38]. Thus, an inflammation
which accompanies CHD may exacerbate loss of NK cells
activity.
Conclusion
Summarizing, our data indicate that coronary heart dis-




Ninety three patients undergoing elective first time coro-
nary artery by-pass grafting from the Clinic of Cardiosur-
gery of the Medical University of Gdańsk were selected.
Basic characteristics of the patients is shown in Table 1.
Hypertension was defined as systolic blood pressure ≥ 140
mm Hg or diastolic blood pressure ≥ 90 mmHg, or
patient's history of anti-hypertensive treatment verified at
admission. Diabetes was defined as fasting glucose ≥ 126
mg/dl, non-fasting glucose ≥ 200 mg/dl, or patient's his-
tory of diabetes verified at admission. Coronary angiogra-
phy was performed in all patients. Patients were qualified
for coronary artery by-pass grafting (CABG) if they had at
least one stenosis with diameter of ≥ 75% in the right cor-
onary artery (RCA) and/or left-anterior descending artery
(LAD) and/or left circumflex artery (CX). Forty nine peo-
ple, of similar age, with excluded coronary heart disease
were enrolled into the study as a control group. The dis-
ease was excluded on the base of physical examination,
lack of clinical symptoms of CHD and normal resting and
exercise-related electrocardiogram. The written informed
consent was obtained from all participants. The present
study was approved by the Ethics Committee of the Med-
ical University of Gdańsk.Immunity & Ageing 2007, 4:3 http://www.immunityageing.com/content/4/1/3
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Specimen collection and isolation of cells
Venous blood samples (10 ml) were collected between
9.00 and 10.00 am aseptically into the tubes with anti-
coagulant (EDTA tubes Medlab, Austria) one day before a
surgery.
The peripheral blood mononuclear cells (PBMC) were
obtained, from venous blood, by centrifugation in Ficoll-
Hypaque gradient. The PBMC were cultured in RPMI
1640 medium with 5% heat-inactivated fetal calf serum
(FCS) on a plastic plate (Gibco, BRL Life Technologies,
USA). After 1 h of incubation, in a humidified atmosphere
containing 5% CO2 at 37°C, non-adherent peripheral
blood lymphocytes (PBL) were collected.
NK cytotoxic assay
Cytotoxic activity of PBL was determined in a colorimetric
assay based on the measurement of lactate dyhydrogenase
(LDH) activity released from the cytosol of damaged K562
target cells (human erythroleukemia cell line) into the
supernatant with the use of the "Cytotoxicity Detection
Kit" (Roche Diagnostics, Germany). The NK-sensitive
K562 tumor line was grown in RPMI 1640 medium sup-
plemented with 5% FCS, 100 μg/ml streptomycin, 100 U/
ml penicillin (Sigma Chemical Co., USA), in a humidified
atmosphere containing 5 CO2 at 37°C. PBL were sus-
pended in RMPI 1640 medium supplemented with 1%
FCS at the concentration of 2 × 105 cells/ml, which was the
optimal concentration of effector cells (PBL) determined
in pilot studies, yielding optimal levels of killing (increas-
ing toward a plateau). Cell cultures of 100 μl PBL (2 × 105
cells/ml) and 100 μl target cells (2 × 10 4 cells/ml) in trip-
licates were incubated in round bottom microtiter plates
for 4 h (effector-target cell ratio = 10:1) in a humidified
atmosphere containing 5 CO2 at 37°C. The plates were
then centrifuged for 10 min at 250 g, 100 μl of the super-
natants were transferred to flat bottom microtiter plates,
and the activity of LDH was determined using the "Cyto-
toxicity Detection Kit" (Roche Diagnostics, Germany).
Optical density was read at 492 nm on the automated
plate reader (Bio-Tek FL600, Bio-Tek Instruments, Inc.
Winooski, USA). Spontaneous LDH release was deter-
mined by incubation of 100 μl target cells with 100 μl
medium. The maximum release was determined by incu-
bation of 100 μl target cells plus 100 μl medium with a
final concentration of 1% Triton X-100 (Sigma Chemical
Co., USA). The percentage of NK cytotoxicity, was calcu-
lated by the following formula: NK cytotoxicity (%) =
[(experimental value - spontaneous release)/(maximum
release - spontaneous release)] × 100 %
Staining of NK cells
The samples of venous blood were aliquoted into plastic
tubes (Falcon, Becton Dickinson Company, USA), 100 μl
per tube. Cells were stained with anti-CD3 (IgG2a,κ
mouse PE-Cy5, Clone: HIT3a, PharMingen, Becton Dick-
inson Company, USA), anti anti-CD56 (IgG1,κ mouse
PE, Clone: B159, PharMingen, Becton Dickinson Com-
pany, USA) human antibodies (20 μg/test). For each set,
appropriate isotypic control was done (IgG2b,κ mouse
PE-Cy5, Clone: 27–35, IgG1k mouse PE, Clone: MOPC-
21, PharMingen, Becton Dickinson Company, USA). After
30 min incubation in the dark at a RT samples were fixed
using Immuno-prep reagents (Immunotech, USA) with
Q-prep Immunology Workstation (Coulter, USA).
Cultures of peripheral blood mononuclear cells
PBMC were obtained by centrifugation in Ficoll-Hypaque
gradient and subsequently cultured on the plastic 24-well
plates in triplicates, 1 × 106 cells per well, in 1 ml of RPMI
containing 5% FCS. The cultures were incubated with
with phorbol 12-myristate 13-acetate [PMA] for 5 hours
(Sigma Chemical Co. USA) and ionomycin (Sigma Chem-
ical Co. USA), both at final concentrations of 50 ng/ml.
Two microliters of GolgiPlug (PharMingen, Becton Dick-
inson, USA) were added together with PMA and ionomy-
cin to avoid a leakage of the cytokine. Control cultures
were incubated for 5 hours (h) only with PMA and iono-
mycin
Staining of intracellular cytokines
The PBMC cultures were vortexed and aliquoted into 12 ×
75 mm plastic tubes (Falcon, Becton Dickinson, USA), 2
× 105 cells per tube. After washing of cells with staining
buffer (PBS without Ca2+ and Mg2+ with 1% heat-inacti-
vated foetal calf serum and 0.09% sodium azide), cells
were stained with anti-CD3 (IgG2a,κ mouse PE-Cy5,
Clone: HIT3a, PharMingen, Becton Dickinson Company,
USA), anti anti-CD56 (IgG1,κ mouse PE, Clone: B159,
PharMingen, Becton Dickinson Company, USA) human
antibodies and incubated 30 min in the dark at a room
temperature (RT). Then, the cells were washed and fixed
in 4% paraformaldehyde (Sigma Chemical Co., USA) in
PBS without Ca2+ and Mg2+, washed and permeabilised
using 0.5 ml of 0.1% saponin (in PBS without Ca2+ and
Mg2+  with 1% heat-inactivated foetal calf serum and
0.09% sodium azide) for 20 min at a RT. Then, the cells
were washed and stained with anti IFN-γ (IgG1,κ mouse
FITC, Clone: B27, Pharmingen, BD USA) and isotype
mAbs (IgG1, κ mouse FITC, Clone: MOPC-21, Pharmin-
gen, BD USA) [1 μg/test] and incubated 30 min in the
dark at a RT. The samples were subsequently washed and
fixed in a solution of PBS containing 2% paraformalde-
hyde (Sigma Chemical Co., USA).
Acquisition and analysis of flow cytometry data
Listmodes were acquired on Epics XL flow cytometer
(Coulter, USA) and analyzed using Winlist, version 5.0,
software. Dead cells were excluded by forward (FSC) and
side (SS) angle scattered light window. The region con-Immunity & Ageing 2007, 4:3 http://www.immunityageing.com/content/4/1/3
Page 7 of 8
(page number not for citation purposes)
taining lymphocytes was generated on the basis of using
their forward versus right angle light scatters. A lym-
phocytes gate was used to measure the proportion of NK
cells subsets in the sample. Typically, 10 000 events were
acquired in this region. The absolute number of cells was
determined by multiplying the respective percentages
obtained by flow cytometry by respective absolute counts
from clinical laboratory reports.
Statistics
Data were computed using program Statistica 6.0
(Statsoft, Poland). Parametric and non-parametric distri-
butions was assessed by W Shapiro-Wilk test. The analysis
was based on non-parametric statistic U-Mann-Whitney
test as indicated by data distribution.
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